Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vertex Pharmaceuticals Incorporated
< Previous
1
2
3
4
Next >
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
November 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex Reports Third Quarter 2023 Financial Results
November 06, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
November 02, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present at Upcoming Investor Conferences
October 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Third Quarter 2023 Financial Results on November 6
October 10, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Appoints Michel Lagarde to its Board of Directors
October 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
October 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
September 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
September 14, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
August 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
August 29, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
August 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Second Quarter 2023 Financial Results on August 1
June 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
June 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
June 23, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
June 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
June 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
June 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
May 30, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
May 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports First Quarter 2023 Financial Results
May 01, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
April 26, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
April 25, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce First Quarter 2023 Financial Results on May 1
April 10, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
April 03, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
March 27, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
March 16, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
March 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.